###### Strengths and limitations of this study

-   Novel and relevant areas of research which will guide future research in this field.

-   Protocol is for the first systematic review to investigate vitamin D and inflammation across all population groups and disease and/or non-disease states.

-   Employs rigorous international gold-standard methodology and comprehensive search strategy.

-   Limited in that the systematic review will include only published data.

Introduction {#s1}
============

Vitamin D has traditionally been known for its role in regulating calcium and phosphorus for the healthy mineralisation of bone. Recent evidence has broadened interest to the role of vitamin D in extraskeletal functions, including in inflammation and immunoregulation.[@R1] [@R2] The functions of vitamin D in inflammation are of increasing interest, and vitamin D deficiency has been implicated in the pathophysiology of various inflammatory diseases including Crohn\'s disease and rheumatoid arthritis, as well as in conditions associated with chronic low-grade inflammation, such as obesity, insulin resistance, type 2 diabetes and cardiovascular disease.[@R3]

The interaction between vitamin D and inflammation may have clinical implications, as vitamin D deficiency remains prevalent worldwide and is increasing as a result of sedentary indoor lifestyles and the use of sunscreen and protective clothing to reduce the risk of skin cancer.[@R4] At present, there is no universal consensus on optimal levels of vitamin D, but most experts agree that plasma 25-hydroxyvitamin D levels \<50 nmol/L would be considered deficient.[@R5] It is therefore concerning that 20--60% of the UK and 10--40% of the US population have vitamin D levels \<50 nmol/L.[@R6] Despite the sunny climate in Australia, vitamin D deficiency is prevalent in 50% of women and 31% of men.[@R7]

Vitamin D can be obtained from dietary sources or supplements in the form of cholecalciferol or ergocalciferol, although it is primarily derived via conversion of 7-dehydrocholesterol in the skin consequent to exposure to ultraviolet B radiation.[@R8] However, recommendations to prevent skin cancer by reducing sun exposure have made it difficult to obtain adequate vitamin D through sun exposure, and limited foods have naturally high vitamin D levels, or are vitamin D fortified.[@R4]

Following ingestion or cutaneous synthesis, vitamin D is hydroxylated by the liver into 25-hydroxyvitamin D~2~ or D~3~ (25OHD) and is then converted to its biologically active form (1,25-dihydroxyvitamin D~2~/D~3~ or 1,25OHD, for short) via a second hydroxylation in the kidney by 25OHD-1α-hydroxylase (CYP27B1).[@R9] 1,25OHD functions as a steroid hormone and binds to a nuclear vitamin D receptor (VDR) which has recently been found in nearly all tissue cells, including most inflammatory cells, with particularly high VDR levels in dendritic cells, macrophages and T and B lymphocytes, thus supporting the notion that vitamin D may have a role in inflammatory and immune responses.[@R10]

Several studies have attempted to delineate the effects of vitamin D on inflammatory cells and processes. In vitro, vitamin D has been shown to promote monocyte differentiation to macrophages, preventing them from releasing inflammatory cytokines and reducing their ability to present antigens to lymphocytes by inhibiting cell surface expression of the class 2 major histocompatibility complex (MHC-II) molecule.[@R2] Vitamin D also suppresses the proliferation and stimulatory abilities of T cells and monocytes, and downregulates proinflammatory cytokines, including C reactive protein (CRP), tumour necrosis factor α (TNFα), interleukin (IL) 6, IL-1 and IL-8, while upregulating anti-inflammatory cytokines such as IL-10.[@R2] In vitro data has also shown associations between absence of the VDR and increased nuclear factor κB (NFκB) activity, a transcription factor with a key role in immunomodulation, and in the pathophysiology of several inflammatory diseases and chronic inflammatory states.[@R11] The reverse was also evident, where vitamin D was shown to prevent NFκB translocation and weaken its activity.[@R11]

In vivo studies using animal models have shown that supplementation with 1,25OHD prevented the development of inflammatory arthritis, type 1 diabetes and autoimmune encephalomyelitis and thyroiditis.[@R12] Administration of 1,25OHD to non-obese, non-diabetic mice also modulated chemokine and cytokine expression and prevented diabetes.[@R16] Conversely, VDR knockout mice developed severe diarrhoea and rectal bleeding, suggesting that vitamin D deficiency may compromise the integrity of the intestinal mucosal barrier, thereby increasing susceptibility to mucosal damage and development of inflammatory bowel disease.[@R17]

Human observational studies have frequently reported that higher vitamin D levels were associated with lower inflammatory markers including CRP, IL-6 and TNFα in healthy populations,[@R18] and in those with proinflammatory conditions, such as diabetes, arteriosclerosis and inflammatory polyarthritis.[@R3] Vitamin D has also been associated with adipocytokines, with studies showing inverse correlations between vitamin D and leptin,[@R21] [@R22] and positive correlations between vitamin D and adiponectin.[@R22] [@R23] This latter action of vitamin D is thought to occur partly via down-regulating IL-6 since IL-6 has been shown to inhibit adiponectin gene expression.[@R23] [@R24]

It is biologically plausible that sufficient vitamin D levels may be important in modulating inflammatory processes, and this seems to be supported by various experimental and observational studies.[@R1] [@R2] However, observational studies are limited given their high risk of bias and inability to establish causation or directionality. Moreover, randomised controlled trials (RCTs) and systematic reviews of RCTs to date have focused on specific population groups, such as children,[@R25] [@R26] or inflammatory conditions, such as obesity, inflammatory bowel disease and chronic obstructive pulmonary disease.[@R27] Thus, there remains a gap in knowledge of the effects of vitamin D supplementation on inflammatory markers or states across the wider general population. This systematic review, therefore, aims to address this gap by identifying and comprehensively synthesising evidence evaluating the effect of vitamin D supplementation on inflammation in all population groups.

Systematic review question {#s2}
==========================

-   Is vitamin D supplementation effective for treatment of inflammation (versus placebo or usual care)?

-   Is vitamin D supplementation better than other non-pharmacological or pharmacological interventions for treatment of inflammation?

Methods/design {#s3}
==============

Rigorous international gold-standard methodology will be adopted in this review,[@R31] [@R32] and will conform to the reporting standards of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). This systematic review has been registered on PROSPERO under the identification code: CRD42016037104.

Eligibility criteria {#s3a}
--------------------

Selection criteria using the PICO (Population, Intervention, Comparison, Outcomes) framework in [table 1](#BMJOPEN2015010804TB1){ref-type="table"} established a priori will be used to determine eligibility of articles.

###### 

PICO for study inclusion

  Participants (P)                                                                                                   Intervention (I)                                                                                                                                                                                     Comparison (C)                                                                                        Outcomes (O)
  ------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Inclusion criteria                                                                                                                                                                                                                                                                                                                                                                                                            
   Males and females of any age, ethnicity, socioeconomic status, geographic area, comorbidity or pregnancy status   Vitamin D~2~ and/or vitamin D~3~ supplementation, administered in any form (intravenous, intramuscular, or oral), alone or combined with other intervention/s, of any dosage, and for any duration   Placebo or usual care. Any other non-pharmacological interventions or pharmacological interventions   Inflammatory biomarkers including, but not limited to: all interleukins, all TNFα, TGF-β1, hs/CRP, MCP-1, ADMA, PAI-1, SAA, IFNγ, NFκB, MIF, ICAMs, fibrinogen, MMPs, adipocytokines: leptin, resistin, visfatin, adiponectin, omentin
  Exclusion criteria                                                                                                                                                                                                                                                                                                                                                                                                            
   None                                                                                                              Studies without vitamin D supplementation                                                                                                                                                                                                                                                                  
  Study type                                                                                                         Systematic reviews of RCTs and RCTs                                                                                                                                                                                                                                                                        
  Language                                                                                                           No limit                                                                                                                                                                                                                                                                                                   
  Year of publication                                                                                                No limit                                                                                                                                                                                                                                                                                                   

ADMA, assymetric dimethylarginine; hsCRP, high sensitivity C reactive protein; ICAMs, intracelleular adhesion molecules; IFNγ, interferon γ; MCP-1, monocyte chemotactic protein 1; MIF, macrophage migration inhibitory factor; MMPs, matrix metalloproteinases; NFκB, nuclear factor κB; PAI-1, plasminogen activator inhibitor 1; RCT, randomised controlled trial; SAA, serum amyloid A; TGF-β1, tumour growth factor 1; TNFα, tumour necrosis factor α.

Search strategy {#s4}
===============

A systemic search will be developed using relevant search terms (see [online supplementary file](#SM1){ref-type="supplementary-material"} 1) in accordance with the selection criteria (table 1), and the following electronic databases will be used: MEDLINE via OVID;MEDLINE in-process and other non-indexed citations via OVID;CINAHL;EMBASE via OVID;All Evidence Based Medicine (EBM) Reviews via OVID incorporating: The Cochrane Library; Cochrane Database of Systematic Reviews (Cochrane Reviews); Database of Abstracts of Reviews of Effects (Other Reviews); Cochrane Central Register of Controlled Trials (Clinical Trials); Cochrane Database of Methodology Reviews (Methods Reviews); The Cochrane Methodology Register (Methods Studies); Health Technology Assessment Database (Technology Assessments); NHS Economic Evaluation Database (Economic Evaluations); and ACP Journal Club.
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Bibliographies of relevant studies identified by the search strategy and relevant reviews/meta-analyses will also be searched for identification of additional studies. Corresponding authors of any included trials where required data are not presented will be contacted to provide deidentified data (aggregated effect measures) for the purpose of meta-analysis, if deemed appropriate. To identify unpublished studies we will also search the National Institute of Health Clinical Trials Register (<https://clinicaltrials.gov/>) and the Australian New Zealand Clinical Trials registries (<https://www.anzctr.org.au>).

Inclusion of studies {#s4a}
--------------------

To determine the literature to be assessed further, one reviewer will scan the titles, abstract sections and keywords of every record retrieved by the search strategy using the selection criteria described in [table 1](#BMJOPEN2015010804TB1){ref-type="table"}, and in consultation with a second reviewer. Disagreement between reviewers about whether a study meets the inclusion criteria will be resolved by discussion. Where consensus is not reached, a third reviewer will be consulted to reach a decision. A pilot test of the selection criteria will be conducted on 3--5 articles in order to refine and clarify the criteria prior to screening.

Full articles will be retrieved for further assessment if the information given suggests that the study meets the selection criteria. Where there is any doubt regarding eligibility from information provided in the title and abstract, the full article will be retrieved for clarification. Studies excluded based on full text will be tabulated with the reason/s for their exclusion.

Quality appraisal of the evidence {#s4b}
---------------------------------

Methodological quality, in terms of risk of bias, of the included studies will be assessed at the study level by two independent reviewers using criteria developed a priori, as outlined in the Monash Centre for Health Research and Implementation critical appraisal template.[@R33] Individual quality items will be investigated using a descriptive component approach that includes items such as conflict of interest of authors, presence of prespecified selection criteria, methods of randomisation and allocation of participants to study groups, blinding of participants, carers, investigators or outcome assessors, methods of outcome assessment and reporting, and statistical issues, such as powering and methods of data analysis (see [online supplementary file](#SM2){ref-type="supplementary-material"} 2). Any disagreement or uncertainty will be resolved by discussion among review authors to reach a consensus. Using this approach, each study will be allocated a risk of bias rating.[@R33]
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Data extraction {#s4c}
---------------

Data will be extracted from all included studies by two independent reviewers using a specifically developed data extraction form in line with the selection criteria and outcomes of interest (table 1). Both reviewers will check all computed data entries for meta-analyses, if applicable.

Extracted data will include mean values and SDs of the outcomes, and their CIs, point estimates and measures of variability, frequency counts for dichotomous variables, number of participants, intention-to-treat analysis, and validity results.

Outcomes may be reported as continuous measures of these inflammatory biomarkers, and in such cases, the mean or standardised mean difference along with their SDs and CIs will be used to measure the effects (see [online supplementary file](#SM2){ref-type="supplementary-material"} 2). Eligible outcomes may also be dichotomous and, as such, will include relative measures of inflammation risk (risk ratio or OR along with CIs), or absolute numbers of patients experiencing at least one episode of inflammation.

Grading the body of evidence {#s4d}
----------------------------

The quality of the evidence for the effects of vitamin D supplementation on inflammatory markers and diseases will be assessed as high, moderate, low or very low using the GRADE approach.[@R34] Quality of evidence will be graded by two independent reviewers based on risk of bias, imprecision, heterogeneity, indirectness and suspicion of publication bias. Quality will be reported at the study level, and where appropriate, at the outcome level, in line with PRISMA guidelines. Disagreements will be resolved by discussion, and where consensus cannot be reached, a third reviewer will be consulted. Interpretation of the grading scores is presented in [table 2](#BMJOPEN2015010804TB2){ref-type="table"}.

###### 

Grading the quality of the evidence (adapted from GRADE Working Group, 2004)[@R34]

  Strength of evidence   Interpretation
  ---------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  High quality           Very confident in the estimate of the effect, and further research is very unlikely to change our confidence.
  Moderate quality       Moderately confident in the estimate of the effect, but further research may have an important impact on our confidence and may change the estimate.
  Low quality            Somewhat confident in the estimate of the effect, but further research is very likely to have an important impact on our confidence and will likely change the estimate.
  Very low quality       Very little confidence in the estimate of the effect as it is very uncertain.

Data analysis and synthesis {#s5}
===========================

Planned analyses {#s5a}
----------------

Data will be presented in summary tables and in narrative form to describe the populations, interventions and outcomes of the included studies. Where data is available, or could be imputed or obtained from authors, between-group differences will be presented, and relative differences in outcomes will be assessed. Log transformation will be conducted where necessary. Aggregated effect measures will be used for meta-analyses where appropriate, when data are derived from clinically homogeneous groups (where participants, interventions and outcome measures are sufficiently similar), using a random effects model in Review Manager 5.3.5. Dichotomous outcomes will be presented as relative risks with 95% CIs, while continuous outcomes will be presented as weighted mean differences with 95% CIs. A p value of \<0.05 will indicate statistical significance.

Statistical heterogeneity will be assessed using the I^2^ test, where I^2^ values over 50% indicate moderate to high heterogeneity. Descriptive analyses will be conducted for those studies which are deemed clinically heterogeneous, or present insufficient data for pooling.

Subgroup and sensitivity analyses {#s5b}
---------------------------------

Subgroup analyses, or if applicable, metaregression analyses will be performed for factors presumed to cause variations in outcomes, and may include age, body mass index, dosage regimen, deficiency of participants at baseline, participant disease status and study duration.

Sensitivity analysis will be conducted if deemed appropriate, and factors to be included will be determined during the review process. Heterogeneity I^2^ \>50% will be explored through sensitivity analysis using risk of bias. For meta-analyses of more than 10 studies, funnel plots will be used to determine small study effects and potential publication bias.

Discussion {#s6}
==========

Although inflammatory processes are crucial for the human host defence against infectious agents and injury, prolonged systemic inflammation contributes to the pathophysiology of many chronic diseases.[@R1] Moreover, there is limited knowledge on the potential of naturally occurring nutrients, such as vitamin D, in improving these inflammatory states and conditions.

To the best of our knowledge, this will be the first comprehensive systematic review investigating the effectiveness of vitamin D supplementation in improving inflammation in all populations, as previous reviews have been limited to investigating specific inflammatory conditions or population groups.[@R26] [@R28] [@R30] In addition, this review will include trials investigating inflammation independently, and/or as a risk factor in the pathophysiology of cardiometabolic diseases such as type 2 diabetes, heart disease or chronic inflammatory conditions such as Crohn\'s disease and rheumatoid arthritis. There is also a lack of sound evidence to justify biological or sociological differences between population subgroups, hence, the additional benefit of including populations of all ages and backgrounds in this review.

Our systematic review will use rigorous methodology, prespecified criteria and predetermined outcomes in order to comprehensively examine and synthesise the literature and assess the effects of vitamin D supplementation on inflammatory markers and diseases in a variety of populations.

Although outside of our control, this systematic review is limited by its reliance on published data, and thus, publication bias cannot be ruled out as there may be unpublished findings that are unaccounted for.

This systematic review will investigate the impact of vitamin D supplementation on inflammation, and identify knowledge gaps to inform future research in the field. If vitamin D supplementation improves inflammation on systematic review and meta-analyses, we will generate level 1 evidence of efficacy with important implications for clinical practice.
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